Your Partner for End-to-end Oncology Drug Development
Bringing an oncology therapy from concept to clinic requires more than manufacturing capacity—it requires a partner who understands what's at stake. As cancer incidence grows globally, the need for scalable, compliant, and rapidly deployable manufacturing solutions has never been greater.
With over 20 years of experience and support for 65% of FDA approved oncology drugs, Charles River delivers the integrated capabilities needed to accelerate the entire oncology drug development process with unmatched reliability and scientific expertise.
Why a Specialized Oncology CDMO Matters: Accelerating Innovation from Concept to Cure
Behind every oncology program is a race against time—tight development timelines, shifting regulatory expectations, and the pressure to produce safe, consistent therapies at scale. Our experts in oncology drug manufacturing solve those challenges holistically. From plasmid DNA and viral vector to cell therapy manufacturing, we streamline workflows, reduce risk, and help ensure oncology therapies reach patients faster.
Oncology Trailblazers
Learn about our oncology partnerships to advance cancer research and drug development through manufacturing services.
Learn More
What Our Clients Say
From blood cancer to targeting solid tumors, we tailor programs for clients with a range of oncology drug development needs.
"Metastasis accounts for approximately 90% of cancer deaths, and there is a gaping therapeutic void for patients with BC-LM, who face a survival window of just 3–15 months. The acceptance into the Charles River Incubator Program not only validates our novel AAV8 approach, but critically, it will accelerate the development and scale-up of our InterAct Print™ platform—the real long-term value driver with true multi-indication optionality. We are honored to partner with Charles River."
Daniel Hargrove, Co-founder and CEO, InterAct Therapeutics
Integrated, Scalable Manufacturing for Oncology Programs
As a fully integrated oncology manufacturer, Charles River provides end-to-end capabilities in immuno-oncology for cancer cells and gene therapy spanning early discovery to clinical trials through commercial launch. Our oncology CDMO services include plasmid DNA, viral vector, and cell therapy manufacturing for CAR-T, CAR-NK, TCR-T, and TILs therapies.
Plasmid DNA Manufacturing Services
Streamline your critical starting materials supply with off-the-shelf plasmids and platform-based production.
- Comprehensive suite of plasmid DNA manufacturing services to support preclinical research through clinical development and commercial supply
- We can work with your existing plasmid for production or generate a custom plasmid tailored to your precise requirements
- Our eXpDNA™ plasmid production platform streamlines manufacturing to 5+ weeks for HQ plasmid and 10+ for GMP
Viral Vector Manufacturing
Scale your viral vector project with comprehensive GMP production services from AAV, lentiviral vector, adenovirus, and retrovirus-based therapies.
- Flexibility of multiple manufacturing platforms and frameworks, with integrated plasmid production capabilities
- From off-the-shelf research product and packaging services to custom GMP viral vector manufacture
- Our Lentivation™ lentiviral vector and nAAVigation® adeno-associated viral vector production platforms reduce production timelines by up to 60%
CAR-T Manufacturing Services
From analytical to process development to optimized CAR-T manufacturing, our experts guide you at every stage of your oncology drug development journey.
- Integrated quality control and biologics testing, we can manage all phases of the drug development lifecycle and supply chain
- Cell therapy manufacturing for both autologous and allogeneic programs with a specialty in immune-based cells
- Our Cell Therapy Flex Platform for autologous T cells significantly shortens cell process development and manufacturing from months to weeks
Production Speed
Platform-based approach combined with parallel processes accelerates drug development and compresses timelines.
Regulatory Expertise
Proven global regulatory compliance with support of both INDs and BLA submissions across modalities.
Streamlined Manufacturing
Integrated biologics testing services ensure seamless coordination and reduced time to the clinic.
Next-Gen Immunotherapy
Deepen your understanding of how to bring immunotherapies to market with this on-demand webinar and eBook that cover improving cell and gene therapy workflows and accelerating development timelines.
Learn More
Global CDMO Center of Excellence
With our global regulatory compliant CDMO facilities, Charles River provides the full suite of immuno-oncology capabilities for cancer cells and gene therapy. Benefit from faster knowledge transfer and reduced bottlenecks from our comprehensive workflow and shared CGT systems.
